• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Chimerix, Inc. - Common Stock (NQ: CMRX )

    3.220 -0.120 (-3.59%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Chimerix, Inc. - Common Stock

    < Previous 1 2 Next >
    Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
    EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures COVID-19
    Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
    From FN Media Group LLC
    Via GlobeNewswire
    Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Appoints Marc D. Kozin to Board of Directors
    Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience 
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Present at TD Cowen 44th Annual Health Care Conference
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Appoints Lisa Decker to Board of Directors
    Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience 
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
    Proven Leader Brings More Than 25 Years of Financial Experience 
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
    Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development 
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix to Participate in Upcoming Investor Conferences
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
    From Chimerix, Inc.
    Via GlobeNewswire
    Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
    From Chimerix, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.